Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Acquired by Nordea Investment Management AB

Nordea Investment Management AB boosted its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 117.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 332,913 shares of the company's stock after acquiring an additional 179,527 shares during the quarter. Nordea Investment Management AB owned 0.37% of Myriad Genetics worth $4,548,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of MYGN. Point72 Hong Kong Ltd purchased a new position in Myriad Genetics in the third quarter worth approximately $32,000. GAMMA Investing LLC lifted its position in shares of Myriad Genetics by 34.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,620 shares of the company's stock worth $44,000 after purchasing an additional 412 shares during the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Myriad Genetics during the 2nd quarter worth $60,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Myriad Genetics during the second quarter worth $82,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Myriad Genetics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company's stock valued at $87,000 after buying an additional 583 shares in the last quarter. 99.02% of the stock is owned by institutional investors and hedge funds.

Myriad Genetics Stock Performance

Myriad Genetics stock traded up $0.05 during mid-day trading on Friday, reaching $14.83. 995,856 shares of the company were exchanged, compared to its average volume of 864,659. The firm's 50-day simple moving average is $15.12 and its two-hundred day simple moving average is $22.26. Myriad Genetics, Inc. has a twelve month low of $12.87 and a twelve month high of $29.30. The firm has a market cap of $1.35 billion, a PE ratio of -11.41 and a beta of 1.89. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on MYGN shares. Leerink Partners cut Myriad Genetics from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $30.00 to $21.00 in a research report on Monday, December 9th. Piper Sandler lowered their price target on Myriad Genetics from $30.00 to $24.00 and set a "neutral" rating for the company in a report on Monday, November 11th. Bank of America cut their price objective on shares of Myriad Genetics from $15.00 to $13.00 and set an "underperform" rating on the stock in a report on Friday, December 13th. StockNews.com upgraded shares of Myriad Genetics from a "hold" rating to a "buy" rating in a report on Thursday. Finally, Leerink Partnrs lowered shares of Myriad Genetics from a "strong-buy" rating to a "hold" rating in a research note on Monday, December 9th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $24.27.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.